Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TTK | P33981 | 2/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362793 | 0.84 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL731072 | 0.80 | KDM4E (0.48) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL29643994 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL7331545 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL31190846 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL5693192 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL14412480 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL7331167 | 0.79 | KDM4E (0.57) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL7329986 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL298966 | 0.79 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | claimed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | claimed |
| EP-2291359-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | claimed |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | claimed |
| WO-2009142569-A1 | PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| US-5543517-A | VIRICIDES | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-06 | — | — | US | claimed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4351570-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347569-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | Ideaya Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-4014886-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-03-29 | — | — | US | disclosed |
| US-4009177-A | Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4009177-A | Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-4002652-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-4002652-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-3966760-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966760-A | 2-Substituted-5,6-dimethoxyindazoles | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | KDM4E 258/4885GAA 3776/4885PDPK1 2217/4885 |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | KDM4E 258/4885GAA 3776/4885PDPK1 2217/4885 |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KDM4E 4274/4885GAA 3721/4885PDPK1 754/4885 |
| US-20100080786-A1 | Phenyl or Pyridinyl Substituted Indazoles Derivatives | CYP3A5, CYP3A43, ABCB1 | KDM4E 3038/4885GAA 482/4885PDPK1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.